Two-year overall survival (OS) rates from a randomized phase 2 trial evaluating the combination of nivolumab (NIVO) and ipilimumab (IPI) Versus IPI in patients with advanced melanoma (MEL) Meeting Abstract

  

Authors:	Postow, M. A.; Chesney, J.; Pavlick, A. C.; Robert, C.; Grossmann, K.; McDermott, D.; Linette, G.; Meyer, N.; Giguere, J.; Agarwala, S. S.; Shaheen, M.; Ernstoff, M. S.; Minor, D. R.; Salama, A.; Taylor, M. H.; Ott, P. A.; Jiang, J.; Horak, C.; Wolchok, J. D.; Hodi, S.
Abstract Title:	Two-year overall survival (OS) rates from a randomized phase 2 trial evaluating the combination of nivolumab (NIVO) and ipilimumab (IPI) Versus IPI in patients with advanced melanoma (MEL)
Meeting Title:	COSA's 43rd Annual Scientific Meeting
Journal Title:	Asia-Pacific Journal of Clinical Oncology
Volume:	12
Issue:	Suppl. 5
Meeting Dates:	2016 Nov 15-17
Meeting Location:	Queensland, Australia
ISSN:	1743-7555
Publisher:	Wiley Blackwell
Date Published:	2016-11-01
Start Page:	130
End Page:	131
Language:	English
ACCESSION:	WOS:000387769900202
PROVIDER:	wos
DOI:	10.1111/ajco.12646
Notes:	Meeting Abstract: 253 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/103350